Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?
Key PointsViking Therapeutics raised $575 million in a supplementary public offering after positive trial results.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.